Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715727 | 0.80 | SLC6A2 (0.38) | LMNATRPM8MEN1KMT2ASLC6A2 | |
| SCHEMBL6719406 | 0.79 | SLC6A2 (0.37) | CYP3A4LMNATSHRTRPM8TP53 | |
| SCHEMBL20264441 | 0.76 | CYP3A4 (0.56) | CYP3A4LMNANPSR1TSHRTRPM8 | |
| SCHEMBL7653267 | 0.75 | CYP3A4 (0.63) | CYP3A4LMNANPSR1TSHRTRPM8 | |
| SCHEMBL1114966 | 0.75 | CYP3A4 (0.49) | CYP3A4LMNANPSR1TSHRTRPM8 | |
| SCHEMBL1114832 | 0.74 | CYP3A4 (0.51) | CYP3A4LMNANPSR1TSHRTRPM8 | |
| SCHEMBL3506072 | 0.74 | TACR3 (0.51) | LMNAKMT2AALDH1A1 | |
| SCHEMBL12679882 | 0.73 | CYP3A4 (0.47) | CYP3A4LMNANPSR1TSHRTRPM8 | |
| SCHEMBL12679962 | 0.72 | CYP3A4 (0.49) | CYP3A4LMNANPSR1TSHRTRPM8 | |
| SCHEMBL7723689 | 0.72 | LMNA (0.63) | CYP3A4LMNANPSR1TSHRTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022528-A2 | ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152741-A1 | Arylglycine derivatives and their use as glycine transport inhibitors | SLC1A2, SLC1A1, SLC7A11 | CYP3A4 403/4885LMNA 3809/4885NPSR1 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.